|
1
|
Di Maio S, Mrak G, Juric-Sekhar G, Born D,
Mantovani A and Sekhar LN: Clinicopathologic assay of 15 tumor
resections in a family with neurofibromatosis type 2. J Neurol Surg
B Skull Base. 73:90–103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Claudio PP, Russo G, Kumar CA, Minimo C,
Farina A, Tutton S, Nuzzo G, Giuliante F, Angeloni G, Maria V, et
al: pRb2/p130, vascular endothelial growth factor, p27 (KIP1) and
proliferating cell nuclear antigen expression in hepatocellular
carcinoma: Their clinical significance. Clin Cancer Res.
10:3509–3517. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Plotkin SR, Stemmer-Rachamimov AO, Barker
FG II, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK and di
Tomaso E: Hearing improvement after bevacizumab in patients with
neurofibromatosis type 2. N Engl J Med. 361:358–367. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yonezawa S, Miwa K, Shinoda J, Nomura Y,
Asano Y, Nakayama N, Ohe N, Yano H and Iwama T: Bevacizumab
treatment leads to observable morphological and metabolic changes
in brain radiation necrosis. J Neurooncol. 119:101–109. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Subbiah V, Slopis J, Hong DS, Ketonen LM,
Hamilton J, McCutcheon IE and Kurzrock R: Treatment of patients
with advanced neurofibromatosis type 2 with novel molecularly
targeted therapies: From bench to bedside. J Clin Oncol.
30:e64–e68. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eminowicz GK, Raman R, Conibear J and
Plowman PN: Bevacizumab treatment for vestibular schwannomas in
neurofibromatosis type two: Report of two cases, including
responses after prior gamma knife and vascular endothelial growth
factor inhibition therapy. J Laryngol Otol. 126:79–82. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Plotkin SR, Merker VL, Halpin C, Jennings
D, McKenna MJ, Harris GJ and Barker FG II: Bevacizumab for
progressive vestibular schwannoma in neurofibromatosis type 2: A
retrospective review of 31 patients. Otol Neurotol. 33:1046–1052.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mautner VF, Nguyen R, Kutta H, Fuensterer
C, Bokemeyer C, Hagel C, Friedrich RE and Panse J: Bevacizumab
induces regression of vestibular schwannomas in patients with
neurofibromatosis type 2. Neuro Oncol. 12:14–18. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mautner VF, Nguyen R, Knecht R and
Bokemeyer C: Radiographic regression of vestibular schwannomas
induced by bevacizumab treatment: Sustain under continuous drug
application and rebound after drug discontinuation. Ann Oncol.
21:2294–2295. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ferrer M, Schulze A, Gonzalez S, Ferreiro
V, Ciavarelli P, Otero J, Giliberto F, Basso A and Szijan I:
Neurofibromatosis type 2: Molecular and clinical analyses in
argentine sporadic and familial cases. Neurosci Lett. 480:49–54.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Akhmametyeva EM, Mihaylova MM, Luo H,
Kharzai S, Welling DB and Chang LS: Regulation of the
neurofibromatosis 2 gene promoter expression during embryonic
development. Dev Dyn. 235:2771–2785. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
London NR and Gurgel RK: The role of
vascular endothelial growth factor and vascular stability in
diseases of the ear. Laryngoscope. 124:E340–E346. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Carlson ML, Tveiten OV, Driscoll CL,
Goplen FK, Neff BA, Pollock BE, Tombers NM, Castner ML, Finnkirk
MK, Myrseth E, et al: Long-term quality of life in patients with
vestibular schwannoma: An international multicenter cross-sectional
study comparing microsurgery, stereotactic radiosurgery,
observation, and nontumor controls. J Neurosurg. 122:833–842. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Narita Y: Drug review: Safety and efficacy
of bevacizumab for glioblastoma and other brain tumors. Jpn J Clin
Oncol. 43:587–595. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fisher LM, Doherty JK, Lev MH and Slattery
WH: Concordance of bilateral vestibular schwannoma growth and
hearing changes in neurofibromatosis 2: Neurofibromatosis 2 natural
history consortium. Otol Neurotol. 30:835–841. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zuniga RM, Torcuator R, Jain R, Anderson
J, Doyle T, Ellika S, Schultz L and Mikkelsen T: Efficacy, safety
and patterns of response and recurrence in patients with recurrent
high-grade gliomas treated with bevacizumab plus irinotecan. J
Neurooncol. 91:329–336. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Riina HA, Burkhardt JK, Santillan A,
Bassani L, Patsalides A and Boockvar JA: Short-term
clinico-radiographic response to super-selective intra-arterial
cerebral infusion of bevacizumab for the treatment of vestibular
schwannomas in neurofibromatosis type 2. Interv Neuroradiol.
18:127–132. 2012.PubMed/NCBI
|
|
18
|
Burkhardt JK, Riina HA, Shin BJ, Moliterno
JA, Hofstetter CP and Boockvar JA: Intra-arterial chemotherapy for
malignant gliomas: A critical analysis. Interv Neuroradiol.
17:286–295. 2011.PubMed/NCBI
|
|
19
|
Lim SH, Ardern-Holmes S, McCowage G and de
Souza P: Systemic therapy in neurofibromatosis type 2. Cancer Treat
Rev. 40:857–861. 2014. View Article : Google Scholar : PubMed/NCBI
|
